Retatrutide Side Effects: What the Clinical Trial Data Shows

Retatrutide (LY3437943) is Eli Lilly's investigational GLP-1, GIP, and glucagon triple agonist, sometimes nicknamed “triple G” or “Godzilla” in consumer coverage for its weight-loss magnitude. The phrase retatrutide side effects covers three separate questions: which adverse events showed up in the trials, how their frequency changed with dose, and how the peer-reviewed safety record compares with alarming headlines about the compound. This page answers each with primary-source data. For the pharmacokinetic backdrop that shapes why side effects cluster during escalation, see the retatrutide half-life page; for the week-by-week escalation schedule itself, see the dosage guide.

What Are the Most Common Retatrutide Side Effects?

For UAE-based researchers, clinics, wellness professionals, and readers evaluating metabolic research peptides, this safety profile matters because retatrutide is an investigational triple-agonist that targets three hormone receptors involved in appetite, blood-sugar control, and broader metabolic effects. This page reviews the retatrutide side effects seen in clinical trials — gastrointestinal side effects, heart-rate changes, dysesthesia, dose escalation, and overall tolerability — then sets them against earlier treatments and approved drugs in the GLP-1 class, corrects misinformation about liver toxicity linked to unapproved or counterfeit products, and explains why purity verification, COA review, and product format matter when assessing any research-peptide safety profile.

The clearest answer comes from the phase 2 obesity trial published in the New England Journal of Medicine in June 2023 (Jastreboff et al., NCT04881760). Across 338 adults with obesity, the most common adverse events in the retatrutide groups were gastrointestinal — nausea, diarrhea, vomiting, and constipation. These were dose-related, mostly mild to moderate in severity, and were partially mitigated by starting at 2 mg rather than 4 mg once weekly.^[1] Overall adverse events were reported in roughly 73% to 94% of retatrutide participants (highest in the 8 mg and 12 mg groups) versus about 70% on placebo, and serious adverse events were uncommon, ranging from 0% to 6% across retatrutide arms versus 4% on placebo.^[1]

The phase 2 type 2 diabetes trial published in The Lancet (Rosenstock et al.) told a consistent story. Mild-to-moderate gastrointestinal events — again nausea, diarrhea, vomiting, and constipation — were reported in 67 of 190 retatrutide participants (35%), ranging from 13% in the lowest-dose group to 50% in the fastest 8 mg escalation group, compared with 13% on placebo and 35% on dulaglutide 1.5 mg. There were no reports of severe hypoglycemia and no deaths during that study.^[2] The low hypoglycemia risk reflects the glucose-dependent nature of the GLP-1 and GIP insulinotropic effects.

Why Do the Side Effects Cluster During Escalation?

Gastrointestinal events were not evenly spread across the trials; they concentrated when the dose went up. Lilly's own summary noted that they “usually occurred during the dose-escalation period” and could be partially mitigated with a lower starting dose.^[1] The mechanism behind this timing is pharmacokinetic. Retatrutide is long-acting, with a half-life of roughly six days, so weekly doses overlap and exposure accumulates over the first several weeks. Each step-up therefore lands on a building plasma profile rather than a single isolated dose, which is why the published escalation blocks are written in four-week steps. The retatrutide half-life page covers that accumulation math in detail.

This is also why trial designers treat time as a tolerability tool. Slow escalation gives the gut time to adapt to accumulating exposure, and the phase 2 data showed that a 2 mg start produced fewer GI events than a 4 mg start at the same maintenance dose.^[1] The receptor pharmacology sits separately from this timing question; the full receptor-by-receptor breakdown lives in the retatrutide research hub.

Does Retatrutide Raise Heart Rate?

Yes. Both phase 2 trials reported a dose-dependent increase in heart rate. In the obesity trial, the increase peaked at 24 weeks and declined thereafter.^[1] A 2023 independent review characterised the rise as up to about 6.7 beats per minute and flagged it as a signal worth watching, since resting heart-rate increases are a recognised effect of GLP-1 receptor agonists as a class.^[4]

Analysts covering the later phase 3 data also noted cardiovascular effects as an area for continued monitoring, including an isolated report of a QT-interval abnormality in a single participant. That single-case observation is not the same as an established population-level risk, and the phase 3 osteoarthritis readout reported improvements in several cardiovascular-risk markers alongside the weight loss.^[6]

The New Phase 3 Signal: Dysesthesia (Skin Sensitivity)

The phase 3 TRIUMPH-4 obesity-and-osteoarthritis trial, reported by Lilly on December 11, 2025, surfaced an adverse event that had not appeared in the phase 2 work: dysesthesia, an abnormal sense of touch in which normal skin sensations feel unusual, tingling, or heightened. It was reported in about 8.8% of participants at the 9 mg dose and 20.9% at the 12 mg dose, versus 0.7% on placebo. Lilly described the events as generally mild and said they infrequently led to discontinuation.^[6]

Wall Street coverage summarised the same signal as a form of cutaneous hyperesthesia occurring in roughly 7% of treated participants versus about 1% on placebo across the readout, and noted it “drew attention” because it was new relative to the mid-stage profile.^[6] The proposed explanation is high receptor occupancy at the GIP and glucagon receptors interacting with peripheral nerves, though the mechanism is not settled. In the type 2 diabetes phase 3 program, both dysesthesia and discontinuation rates were reported as notably lower than in the obesity population. Across longer follow-up, average weight loss reached about 28.3% at 80 weeks on the 12 mg dose, underscoring the broader weight loss results that ran alongside continued safety monitoring.

Does Retatrutide Cause Liver Damage? Reading the Data vs the Headlines

This is where the public record and the tabloid framing diverge most sharply. In July 2026, UK outlets ran headlines describing the “Godzilla” jab as “linked to deadly liver damage,” following an alert from the Victorian Department of Health in Australia about six cases of acute liver toxicity since January 2026.^[7] The critical detail those headlines buried is that the Australian health authority explicitly attributed the cases to unapproved peptide products labelled retatrutide — black-market material of unverified content, with the toxicity “possibly linked to a contaminant.” Regulators urged anyone using such products to stop and seek care, and stressed that retatrutide remains investigational and unlicensed by any drug regulator.^[7]

The peer-reviewed trial data point the opposite way on the liver. In the MASLD phase 2a substudy published in Nature Medicine (Sanyal et al., 2024), retatrutide reduced liver fat by roughly 51%, 59%, 82%, and 86% at 24 weeks for the 1, 4, 8, and 12 mg doses respectively, versus about a 5% reduction on placebo. Hepatic steatosis resolved (liver fat below 5%) in more than 85% of participants in the two highest-dose groups, and the authors reported no hepatotoxicity signals in the overall obesity population or the MASLD subset through 48 weeks.^[3]

The distinction is not a marketing point; it is the whole point. A regulated, characterised molecule studied under trial conditions reduced liver fat, while unregulated products sold under the same name — with no guarantee of identity, purity, or sterility — were associated with acute liver injury. That gap is exactly why product identity, third-party purity testing, and certificate-of-analysis documentation matter, and why Remy Peptides supplies material strictly for in-vitro laboratory research rather than human use. Researchers verifying batch documentation can review the Dubai research guide verification page and the compound's format and COA overview.

Gallbladder, Pancreas, and Other Less Common Findings

Beyond the dominant gastrointestinal and heart-rate findings, the trials logged a handful of less frequent events consistent with the incretin drug class. Rapid, substantial weight loss is itself a recognised risk factor for gallbladder events, and gallbladder-related adverse events were noted at higher doses in the obesity program.^[1] As with other GLP-1-based agents, pancreatic-enzyme changes and isolated pancreatitis events are monitored in these programs, and the published safety narratives describe such events as uncommon rather than characteristic. Retatrutide also slows gastric emptying — a recognised incretin-class effect — which is why the trial literature flags altered absorption of co-administered oral medications, including some diabetes medications, as a monitoring consideration in these populations.

It is worth restating the boundary the trials draw: these are reported adverse events in monitored clinical populations, recorded in third-person trial data. They are not a personal risk profile, a dosing recommendation, or medical advice. The severity, timing, and management of any event in a supervised trial reflect a controlled setting that has nothing in common with unsupervised use of unverified material.

Where the Phase 3 TRIUMPH Program Stands

The side-effect picture is still being filled in as Lilly's phase 3 TRIUMPH program reports out. TRIUMPH-4 (obesity with knee osteoarthritis) was the first successful phase 3 readout, disclosed December 11, 2025, with placebo-adjusted weight reduction of about 26.6% and the dysesthesia signal described above.^[6] For comparison, semaglutide typically produces about 14.9% weight loss at 68 weeks in trial settings, which is part of why retatrutide has drawn attention for greater average weight loss. The broader TRIUMPH program spans obesity, overweight with comorbidities, type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis, with several additional readouts expected through 2026. A separate diabetes-focused phase 3 track, TRANSCEND-T2D, reported its first trial in early 2026 with lower dysesthesia and discontinuation rates than the obesity population.

Because retatrutide is not yet approved anywhere, its full labelled safety profile does not exist yet. Its FDA approval status remains investigational — it is not FDA-approved at this stage — and ongoing phase 3 clinical trials are what ultimately determine whether it, like other new weight-loss drugs, reaches the market. For the regulatory timeline, the retatrutide approval tracker follows filing and review status; for how tolerability shapes the escalation schedule, the dosage guide maps the four-week step-ups the trials used.